**Core Concept**
Rituximab is a monoclonal antibody targeting the CD20 antigen on B cells, leading to their depletion through mechanisms involving complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity.

**Why the Correct Answer is Right**
Rituximab is primarily used in the treatment of B-cell lymphomas, such as follicular lymphoma and diffuse large B-cell lymphoma, as well as autoimmune diseases like rheumatoid arthritis and Wegener's granulomatosis. Its efficacy in these conditions is attributed to the depletion of autoreactive B cells and the subsequent reduction in disease activity.

**Why Each Wrong Option is Incorrect**
**Option A:** While rituximab is not used in this condition, it's worth noting that it can be used in the treatment of certain types of multiple myeloma in conjunction with other therapies. However, this option does not accurately represent a condition where rituximab is not used.

**Option B:** This is the correct answer. Rituximab is not used in the treatment of multiple sclerosis, which primarily involves the use of disease-modifying therapies like interferons, glatiramer acetate, and natalizumab.

**Option C:** While rituximab is not used as a first-line treatment for lupus nephritis, it can be used off-label in certain cases.

**Option D:** Rituximab is not typically used in the treatment of Crohn's disease, which is usually managed with anti-TNF-alpha agents like infliximab.

**Clinical Pearl / High-Yield Fact**
When using rituximab, it's essential to consider the risk of reactivation of latent infections, particularly hepatitis B, due to the depletion of B cells.

**Correct Answer: B. Multiple sclerosis. Rituximab is not used in the treatment of multiple sclerosis.**